TScan Therapeutics Terminates Agreement, Incurs Obligation
Ticker: TCRX · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1783328
| Field | Detail |
|---|---|
| Company | Tscan Therapeutics, Inc. (TCRX) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $52,500,000, $32,500,000, $20,000,000, $17.2 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement-termination, financial-obligation
TL;DR
TScan terminated a deal and now has a new financial obligation.
AI Summary
TScan Therapeutics, Inc. announced on December 20, 2024, the termination of a material definitive agreement and the creation of a direct financial obligation. The company, incorporated in Delaware with its principal executive offices in Waltham, Massachusetts, filed this 8-K report on December 23, 2024.
Why It Matters
The termination of a material agreement and the creation of a new financial obligation can significantly impact a company's financial health and strategic direction.
Risk Assessment
Risk Level: medium — The termination of a material agreement and the creation of a new financial obligation suggest potential financial or strategic shifts that warrant closer examination.
Key Players & Entities
- TScan Therapeutics, Inc. (company) — Registrant
- December 20, 2024 (date) — Earliest event reported
- December 23, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Waltham, Massachusetts (location) — Principal executive offices
FAQ
What was the material definitive agreement that TScan Therapeutics terminated?
The filing does not specify the details of the material definitive agreement that was terminated.
What is the nature of the direct financial obligation created by TScan Therapeutics?
The filing indicates the creation of a direct financial obligation but does not provide specific details about its nature or terms.
What is the effective date of the termination and the creation of the financial obligation?
The earliest event reported is December 20, 2024, which is when these actions likely took effect.
Why did TScan Therapeutics terminate the material definitive agreement?
The filing does not provide a reason for the termination of the material definitive agreement.
What are the potential financial implications of the new obligation for TScan Therapeutics?
The filing does not detail the specific financial implications of the newly created obligation.
Filing Stats: 1,408 words · 6 min read · ~5 pages · Grade level 11.5 · Accepted 2024-12-23 07:27:01
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share TCRX The Nasdaq Global Ma
- $52,500,000 — Agreement, the Lender will extend up to $52,500,000 in a term loan facility, consisting of
- $32,500,000 — ility, consisting of a first tranche of $32,500,000 fully funded on the Effective Date (the
- $20,000,000 — Loan Advance ") and a second tranche of $20,000,000 to be available to the Company at the L
- $17.2 m — d all outstanding obligations, totaling $17.2 million, and terminated its Loan and Secu
- $2.1 million — yment premium in an aggregate amount of $2.1 million. The description of the terms of the
Filing Documents
- d920508d8k.htm (8-K) — 35KB
- d920508dex101.htm (EX-10.1) — 288KB
- d920508dex991.htm (EX-99.1) — 14KB
- g920508g1223055456847.jpg (GRAPHIC) — 3KB
- 0001193125-24-283673.txt ( ) — 548KB
- tcrx-20241220.xsd (EX-101.SCH) — 3KB
- tcrx-20241220_lab.xml (EX-101.LAB) — 18KB
- tcrx-20241220_pre.xml (EX-101.PRE) — 11KB
- d920508d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Loan and Security Agreement, dated December 20, 2024, by and among TScan Therapeutics, Inc. and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company 99.1 Press Release of TScan Therapeutics, Inc., dated December 23, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document). Certain portions of this exhibit have been omitted because they are not material and would likely cause competitive harm to the registrant if disclosed.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TScan Therapeutics, Inc. Date: December 23, 2024 By: /s/ Jason A. Amello Name: Jason A. Amello Title: Chief Financial Officer